Renowned stock market investor Rekha Rakesh Jhunjhunwala, along with her associated entities, manages an equity portfolio valued at over ₹67,000 crore. A significant portion of this wealth, specifically more than ₹52,000 crore, is derived from just seven primary stock holdings.
The Core Seven Holdings
As of March 31, 2026, these seven companies represent the most substantial investments within the Jhunjhunwala portfolio, showcasing a concentrated investment strategy.
Titan Company Ltd.
Titan Company remains the most valuable holding in the portfolio, with a worth close to ₹19,840 crore. Rekha Jhunjhunwala holds 4,71,84,470 shares, equating to a 5.31 percent stake. Despite a recent 10 percent dip following a call to avoid gold purchases, the Tata Group's jewellery arm reported a 35 percent year-on-year (YoY) net profit increase to ₹1,179 crore, with total income rising 46 percent YoY to ₹20,300 crore. The company declared a ₹15 per share dividend. Analysts from Elara Capital and Emkay Global have issued 'buy' or 'add' ratings, with target prices ranging from ₹5,000 to ₹5,350.
Inventurus Knowledge Solutions Ltd (IKS)
Listed in December 2024, IKS is the second most valued stock, with Rekha Jhunjhunwala and various trusts collectively owning 8,46,68,326 equity shares, or a 49.3 percent stake, valued at ₹14,728 crore. IKS reported a 133 percent YoY jump in net profit to ₹147.8 crore in Q1 2026, with revenue growing 17 percent YoY to ₹724 crore. The company announced the acquisition of TruBridge, a US-based healthcare IT and RCM provider. Motilal Oswal has a 'buy' rating with a target price of ₹1,902, while JM Financial has an 'add' rating with a target of ₹1,750.
Star Health and Allied Insurance Company Ltd
Jhunjhunwala and associates hold 10,07,53,935 equity shares (17.12 percent stake) in Star Health, valued at ₹5,210 crore. The company saw a significant increase in net profit to ₹111.34 crore, with gross written premium up 16 percent YoY to ₹5,968 crore. YES Securities and Goldman Sachs recommend 'buy' ratings, targeting ₹650 and ₹575 respectively.
Metro Brands
Three discretionary trusts associated with the Jhunjhunwala family hold 3,91,53,600 equity shares (14.37 percent stake) in Metro Brands, valued at ₹4,035 crore. While Q4FY26 net profit slipped 38.7 percent YoY, revenue increased by 10.3 percent YoY to ₹643 crore. Centrum Broking maintains a 'buy' rating with a target of ₹1,475, and HDFC Securities recently upgraded the stock to 'buy'.
Concord Biotech Ltd
The portfolio includes 2,51,99,240 equity shares (24.09 percent stake) in Concord Biotech, worth ₹3,020 crore. Antique Stock Broking has a 'buy' rating with a target price of ₹1,380, though Citi maintains a 'neutral' rating with a trimmed target of ₹1,190.
Fortis Healthcare Ltd
Holdings in Fortis Healthcare amount to 3,03,50,125 equity shares (24.02 percent stake), valued at ₹2,950 crore. Axis Direct and PL Capital both have 'buy' recommendations, with target prices of ₹1,039 and ₹1,050 respectively.
Tata Motors Ltd (TMCV)
Jhunjhunwala's portfolio includes 4,87,48,260 equity shares (1.32 percent stake) in Tata Motors, valued at ₹2,005 crore. YES Securities has an 'add' rating with a target of ₹440, while Emkay has a 'buy' rating at ₹750.